The calculation of the economic burden of insulin injection-related LH in China LH population among insulin-injecting The cost of insulin excess usage among diabetic patients with LH Lipohypertrophy (LH) is a relatively common complication of injecting insulin. It is reported to impair insulin absorption and may increase total daily dose (TDD) of insulin and associated costs. The economic burden of LH is unknown in China. This study aims to evaluate the effects of LH on TDD of insulin and explore potential health economic implications for China.
Objectives
The following data were extracted from a literature review and the IMS Health Report (Diabetes China 2013):
• Insulin-injecting diabetes population in China 1 • Prevalence of LH among insulin-injecting Chinese patients 2 • TDD of insulin among patients with LH (estimated from a recent Spanish study 3 )
• Average unit cost of insulin in China 1 Cost of excess insulin use was calculated per annum. All monetary values were converted to 2013 RMB, with a RMB-USD exchange rate of 6.14:1.
Methods

•
There are approximately 8. 
Results
• LH may represent a significant, addressable, economic burden in China due to excess insulin consumption. Taking steps to reduce LH may reduce healthcare costs in China.
• Additional studies should be conducted on LH prevalence, glycemic control (HbA1c, hyper-and hypoglycemia) and health resource utilization patterns specifically among the Chinese insulininjecting population to validate and extend these findings.
Conclusion
